Phase I study of multi-gene cell therapy in patients with peripheral artery disease

Alternative treatment strategies for claudication are needed and cell-based therapies designed to induce angiogenesis are promising. The purpose of this report was to conduct a Phase I safety, dose-escalating, non-randomized, open-label study of autologous, fully differentiated venous endothelial and smooth muscle cells called MultiGeneAngio (MGA) for claudication due to peripheral artery disease. Twelve subjects, at two centers, received a single intra-arterial infusion of a suspension of equal amounts of transduced autologous venous smooth muscle cells expressing vascular endothelial growth factor (VEGF165) and endothelial cells expressing angiopoietin-1 (Ang-1) (Cohort 1: 1 x 107, Cohort 2: 2 x 107, Cohort 3: 5 x 107, Cohort 4: 7 x 107). The treatment was given unblinded and in the more symptomatic lower extremity. Transduced cells were tested for in vitro doubling time, telomerase activity, and gene expression. The main outcomes were clinical safety and tolerability. Other safety measures included ankle–brachial index (ABI) and walking time on a treadmill. All subjects were male (mean age 60 ± 5 years) including 25% with diabetes mellitus. At 1-year follow-up, there was one serious adverse event possibly related to MGA. Safety endpoints including VEGF and Ang-1 plasma protein levels were within normal ranges in all subjects. The mean maximal walking time increased from baseline to 1 year and the index limb ABI was unchanged, indicating no safety concerns. MGA...

Source: Vascular Medicine - January 27, 2016 Category: Internal Medicine Authors: Grossman, P. M., Mohler, E. R., Roessler, B. J., Wilensky, R. L., Levine, B. L., Woo, E. Y., Upchurch, G. R., Schneiderman, J., Koren, B., Hutoran, M., Gershstein, D., Flugelman, M. Y. Tags: Original Articles Source Type: research